Novo Nordisk shares rose nearly 6% pre-market after UK regulators approved a higher weekly Wegovy dose of up to 7.2 mg for obese adults. The approval allows three weekly injections for patients with a BMI of 30 or higher, expanding treatment flexibility and boosting investor optimism around the drugs growth potential.